Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline

Journal of Dermatology

Volumn 38, Issue 5, 2011, Pages 510-513

  Kim, Jae Hong ^a   Oh, Yoon Seok ^a   Ji, Jae Hong ^a   Bak, Hana ^a   Ahn, Sung Ku ^a,b  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR; CHOLESTEROL; LEUKOTRIENE B4; METRONIDAZOLE; MINOCYCLINE; OXYMETAZOLINE; TRIACYLGLYCEROL; XYLOMETAZOLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ARACHIDONIC ACID METABOLISM; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; ERYTHEMA; ERYTHEMATOTELANGIECTATIC TYPE ROSACEA; FEMALE; FLUSHING; HUMAN; INTRAOCULAR HYPERTENSION; LETTER; LOW LEVEL LASER THERAPY; MEDICAL HISTORY; PAPULE; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRURITUS; PUSTULE; REBOUND; ROSACEA; TACHYPHYLAXIS; TELANGIECTASIA; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; FACIAL DERMATOSES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; ROSACEA; TREATMENT OUTCOME;

EID: 79955377117     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00999.x     Document Type: Letter

References (10)

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587.
2. Crawford GH, Pelle MT, James WD,. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341. (quiz 342-4) (Pubitemid 39178655)
3. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512. (quiz 513-4)
4. Ahlquist RP,. The adrenotropic receptor-detector. Arch Int Pharmacodyn Ther 1962; 139: 38-41.
5. Guimaraes S, Moura D,. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319-356. (Pubitemid 32476119)
6. Civantos Calzada B, Aleixandre de Artinano A,. Alpha-adrenoceptor subtypes. Pharmacol Res 2001; 44: 195-208. (Pubitemid 32889462)
7. Leech CJ, Faber JE,. Different alpha-adrenoceptor subtypes mediate constriction of arterioles and venules. Am J Physiol 1996; 270: H710-H722.
8. Shanler SD, Ondo AL,. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-1371. (Pubitemid 350146279)
9. Beck-Speier I, Dayal N, Karg E, et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther 2006; 316: 843-851. (Pubitemid 43131014)
10. Graf P,. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology 1996; 34: 9-13. (Pubitemid 26155374)